Nicotinamide derivates useful as P38 inhibitors
Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
1. A method for treating Chronic Obstructive Pulmonary Disease comprising administering to a patient in need thereof a compound of Formula (I):
wherein
R 1 is selected from hydrogen, C 1-6 alkyl optionally substituted by up to three groups selected from C 1-6 alkoxy, halogen and hydroxy, C 2-6 alkenyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, phenyl optionally substituted by up to three groups selected from R 5 and R 6 , and heteroaryl optionally substituted by up to three groups selected from R 5 and R 6 ,
R 2 is selected from hydrogen, C 1-6 alkyl and —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
or (CH 2 ) m R 1 and R 2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C 1-6 alkyl groups;
R 3 is chloro or methyl;
R 4 is the group —NH—CO—R 7 or —CO—NH—(CH 2 ) q —R 8 ;
R 5 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , —SO 2 NHR 9 , —(CH 2 ) s NHSO 2 R 10 , halogen, CN, OH, —(CH 2 ) s NR 11 R 12 , and trifluoromethyl;
R 6 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl and —(CH 2 ) s NR 11 R 12 ;
R 7 is selected from hydrogen, C 1-6 alkyl, —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, trifluoromethyl, —(CH 2 ) r heteroaryl optionally substituted by R 13 and/or R 14 , and —(CH 2 ) r phenyl optionally substituted by R 13 and/or R 14 ;
R 8 is selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, CONHR 9 , phenyl optionally substituted by R 13 and/or R 14 , and heteroaryl optionally substituted by R 13 and/or R 14 ;
R 9 and R 10 are each independently selected from hydrogen and C 1-6 alkyl,
or R 9 and R 10 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring may be substituted by up to two C 1-6 alkyl groups;
R 11 is selected from hydrogen, C 1-6 alkyl and —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
R 12 is selected from hydrogen and C 1-6 alkyl,
or R 11 and R 12 , together with the nitrogen atom to which they are bound, form a five or six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 ;
R 13 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, —(CH 2 ) s NR 11 R 12 , trifluoromethyl, phenyl optionally substituted by one or more R 14 groups and heteroaryl optionally substituted by one or more R 14 groups;
R 14 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl and —NR 11 R 12 ;
R 15 is selected from hydrogen and methyl;
X and Y are each independently selected from hydrogen, methyl and halogen;
Z is halogen;
m is selected from 0, 1, 2, 3 and 4, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from C 1-6 alkyl and halogen;
n is selected from 0, 1 and 2;
q is selected from 0, 1 and 2;
r is selected from 0 and 1; and
s is selected from 0, 1, 2 and 3
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R 1 is selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, phenyl optionally substituted by up to three substituents selected from R 5 and R 6 , heteroaryl optionally substituted by up to three substituents selected from R 5 and R 6 .
3. The method according to claim 1 wherein R 2 is hydrogen.
4. The method according to claim 1 wherein R 3 is methyl.
5. The method according to claim 1 wherein X is fluorine.
6. The method according to claim 1 wherein R 7 is selected from C 1-6 alkyl,
—(CH 2 ) q —C 3-7 cycloalkyl, trifluoromethyl, —(CH 2 ) r heteroaryl optionally substituted by R 13 and/or R 14 , and —(CH 2 ) r phenyl optionally substituted by C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, trifluoromethyl, phenyl optionally substituted by one or more R 14 groups and/or heteroaryl optionally substituted by one or more R 14 groups.
7. The method according to claim 1 wherein R 8 is selected from C 3-7 cycloalkyl, CONHR 9 , heteroaryl optionally substituted by R 13 and/or R 14 , and phenyl optionally substituted by C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, trifluoromethyl, phenyl optionally substituted by one or more R 14 groups and/or heteroaryl optionally substituted by one or more R 14 groups.
8. The method according to claim 1 wherein the compound of Formula (I) is as defined in any one of Examples 1 to 123.
9. The method according to claim 1 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide, or a pharmaceutically acceptable salt thereof.
10. The method according to claim 1 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide.
11. The method according to claim 1 wherein the compound of Formula (I) is administered in a pharmaceutical composition comprising an effective amount of a compound, or a pharmaceutically acceptable salt thereof according to Formula (I), in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
12. The method according to claim 1 wherein the compound of Formula (I) is in combination with a second therapeutic agent.
13. The method according to claim 12 wherein the compound of Formula (I) and the second therapeutic agent are administered together or separately.
14. The method according to claim 1 wherein the dose of a compound of Formula (I) in a human is from about 0.1 mg/kg to 10 mg/kg.
15. The method according to claim 9 wherein the dose is from about 0.1 mg/kg to 10 mg/kg.
16. The method according to claim 10 wherein the dose is from about 0.1 mg/kg to 10 mg/kg.
17. The method according to claim 12 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide, or a pharmaceutically acceptable salt thereof.
18. The method according to claim 12 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide.